SEHK:1951

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Jinxin Fertility Group

Executive Summary

Jinxin Fertility Group Limited provides assisted reproductive services (ARS) in China and the United States. More Details


Snowflake Analysis

Flawless balance sheet with proven track record.

Share Price & News

How has Jinxin Fertility Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1951 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 1951's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

10.5%

1951

7.9%

HK Healthcare

5.7%

HK Market


1 Year Return

34.6%

1951

-11.4%

HK Healthcare

14.3%

HK Market

Return vs Industry: 1951 exceeded the Hong Kong Healthcare industry which returned -11.4% over the past year.

Return vs Market: 1951 exceeded the Hong Kong Market which returned 14.3% over the past year.


Shareholder returns

1951IndustryMarket
7 Day10.5%7.9%5.7%
30 Day1.3%7.6%13.6%
90 Day63.4%23.1%19.6%
1 Year35.3%34.6%-9.1%-11.4%18.9%14.3%
3 Yearn/a-40.8%-44.6%-2.9%-13.1%
5 Yearn/a-20.5%-28.4%70.9%42.2%

Long-Term Price Volatility Vs. Market

How volatile is Jinxin Fertility Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Jinxin Fertility Group undervalued compared to its fair value and its price relative to the market?

10.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1951 (HK$15.34) is trading below our estimate of fair value (HK$17.09)

Significantly Below Fair Value: 1951 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 1951 is poor value based on its PE Ratio (86.4x) compared to the HK Healthcare industry average (21.6x).

PE vs Market: 1951 is poor value based on its PE Ratio (86.4x) compared to the Hong Kong market (11.9x).


Price to Earnings Growth Ratio

PEG Ratio: 1951 is poor value based on its PEG Ratio (3.7x)


Price to Book Ratio

PB vs Industry: 1951 is overvalued based on its PB Ratio (4.1x) compared to the HK Healthcare industry average (1.5x).


Next Steps

Future Growth

How is Jinxin Fertility Group forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

23.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1951's forecast earnings growth (23.4% per year) is above the savings rate (1.5%).

Earnings vs Market: 1951's earnings (23.4% per year) are forecast to grow faster than the Hong Kong market (21.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1951's revenue (18.9% per year) is forecast to grow faster than the Hong Kong market (14.2% per year).

High Growth Revenue: 1951's revenue (18.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1951's Return on Equity is forecast to be low in 3 years time (9.5%).


Next Steps

Past Performance

How has Jinxin Fertility Group performed over the past 5 years?

38.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1951 has high quality earnings.

Growing Profit Margin: 1951's current net profit margins (24.2%) are higher than last year (20.7%).


Past Earnings Growth Analysis

Earnings Trend: 1951's earnings have grown significantly by 38.6% per year over the past 5 years.

Accelerating Growth: 1951's earnings growth over the past year (31.7%) is below its 5-year average (38.6% per year).

Earnings vs Industry: 1951 earnings growth over the past year (31.7%) exceeded the Healthcare industry -9.1%.


Return on Equity

High ROE: 1951's Return on Equity (4.8%) is considered low.


Next Steps

Financial Health

How is Jinxin Fertility Group's financial position?


Financial Position Analysis

Short Term Liabilities: 1951's short term assets (CN¥3.4B) exceed its short term liabilities (CN¥610.7M).

Long Term Liabilities: 1951's short term assets (CN¥3.4B) exceed its long term liabilities (CN¥902.6M).


Debt to Equity History and Analysis

Debt Level: 1951 is debt free.

Reducing Debt: 1951 has not had any debt for past 5 years.

Debt Coverage: 1951 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 1951 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Jinxin Fertility Group current dividend yield, its reliability and sustainability?

0.44%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 1951's dividend (0.44%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.04%).

High Dividend: 1951's dividend (0.44%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.52%).


Stability and Growth of Payments

Stable Dividend: 1951 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.

Growing Dividend: 1951 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 1951 is not paying a notable dividend for the Hong Kong market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1951's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Ying Zhong (61 yo)

3.5yrs

Tenure

Mr. Ying Zhong has been an Executive Director and Chief Executive Officer of Jinxin Fertility Group Limited since August 17, 2018 and July 4, 2017, respectively. He joined Jinxin Fertility Group in March 2...


Leadership Team

NamePositionTenureCompensationOwnership
Ying Zhong
CEO & Executive Director3.5yrsno datano data
Yang Dong
Co-CEO & Executive Director2.67yrsno datano data
Yong Zhong
Vice Chairman & Executive Director0.58yrno datano data
Fei You
Chief Financial Officer2.25yrsno datano data
Meixi Deng
Chief Compliance Officer2yrsno datano data
John Wilcox
Executive Director2.08yrsno datano data
Ling Chi
Chief Scientific Officer2.33yrsno datano data
Yong Zeng
Senior Vice President2.33yrsno datano data
Hongkun Liu
Joint Company Secretary2yrsno datano data
Suet Wing Leung
Joint Company Secretary2yrsno datano data

2.0yrs

Average Tenure

48yo

Average Age

Experienced Management: 1951's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ying Zhong
CEO & Executive Director3.5yrsno datano data
Yang Dong
Co-CEO & Executive Director2.67yrsno datano data
Yong Zhong
Vice Chairman & Executive Director0.58yrno datano data
John Wilcox
Executive Director2.08yrsno datano data
Min Fang
Non-Executive Director2.08yrsno datano data
Haw Lim
Independent Non Executive Director1.58yrsno datano data
Yat Keung Chong
Independent Non-Executive Director1.58yrsno datano data
Bin Wang
Chairman2.08yrsno datano data
Changqing Ye
Independent Non-Executive Director1.58yrsno datano data
Zhe Hu
Non-Executive Director2.08yrsno datano data
Xiaobo Wang
Independent Non-Executive Director1.58yrsno datano data

2.1yrs

Average Tenure

49yo

Average Age

Experienced Board: 1951's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Jinxin Fertility Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Jinxin Fertility Group Limited
  • Ticker: 1951
  • Exchange: SEHK
  • Founded: 2003
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: HK$38.210b
  • Shares outstanding: 2.43b
  • Website: https://www.jxr-fertility.com

Number of Employees


Location

  • Jinxin Fertility Group Limited
  • No. 301
  • North Jingsha Road
  • Chengdu
  • Sichuan Province
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1951SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDJun 2019
3NXDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2019
1951SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)YesOrdinary SharesHKHKDJun 2019
1951SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)YesOrdinary SharesHKHKDJun 2019

Biography

Jinxin Fertility Group Limited provides assisted reproductive services (ARS) in China and the United States. The company primarily offers its patients with two treatment solutions, including artificial ins...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/21 10:03
End of Day Share Price2021/01/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.